Datapoint: Lynparza Scores New Prostate Cancer Nod

The FDA on June 1 approved AstraZeneca and MSD’s Lynparza (olaparib) for the treatment of deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) in adult patients, in combination with Johnson & Johnson’s Zytiga and a corticosteroid. The new indication covers about 10% of mCRPC patients. Lynparza, a PARP inhibitor, was first approved in December 2014 for the treatment of advanced ovarian cancer. For this indication, it holds preferred status for 14.6% of all insured lives under the pharmacy benefit, growing to 47% with utilization management restrictions applied.

SOURCE: MMIT Analytics, as of 6/5/23

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 20

Datapoint: Ipsen’s Latest Accelerated Approval Will Challenge Intercept’s Ocaliva

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 18

Datapoint: Texas Won’t Halt Latest Medicaid Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
June 17

Datapoint: Oscar Plans to Double Enrollment by 2027

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today